paroxetine

Trade name: paxil

Small moleculeapproved

Approved

Dec 29, 1992

Paroxetine, also known by the trade names Paxil and Seroxat. PAXIL (paroxetine hydrochloride) is an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate. It is used to treat major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder and premenstrual dysphoric disorder. Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown. Paroxetine, a phenylpiperidine derivative, was originally developed in 1975 by Jorgen Buus-Lassen and associates working in a small Danish company Ferrosan. Paroxetine was the second SSRI synthesized by Buus-Lassen In 1975. — NCATS

Clinical trial activity

240 trials · 222 clinical orgs · 30 marketing orgs

Phase 1
49
Phase 2
82
Phase 3
51
Phase 4
67

Earliest trial started Sep 1, 1996 (NCT00018733)

Timeline

1990s

  1. Dec 29, 1992

    Apotex — Earliest FDA Approval

  2. Dec 29, 1992

    Apotex — NDA Secondary Org

  3. Dec 29, 1992

    Apotex — NDA Organization

  4. Jan 1, 1997

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

  3. Jul 3, 2003

    Sebela Pharmaceuticals — NDA Secondary Org

  4. Jul 30, 2003

    Apotex — Marketing Organization

  5. Mar 8, 2004

    Mylan — Marketing Organization

  6. Mar 8, 2004

    Upsher-Smith Laboratories — Marketing Organization

  7. Mar 8, 2004

    PHARMOBEDIENT — Marketing Organization

  8. Aug 15, 2005

    Chartwell Pharmaceuticals — Marketing Organization

  9. Mar 7, 2007

    Zydus Discovery DMCC — Marketing Organization

  10. Jun 29, 2007

    Roxane Laboratories — Marketing Organization

  11. Jun 29, 2007

    Sun Pharmaceuticals — Marketing Organization

  12. Jun 29, 2007

    Teva — Marketing Organization

  13. Jun 29, 2007

    Boehringer Ingelheim — Marketing Organization

  14. Jul 25, 2007

    Aurobindo Pharma — Marketing Organization

2010s

  1. Jun 21, 2010

    Oxford Pharmaceuticals — Marketing Organization

  2. Jun 28, 2013

    LEGACY PHARMA — Marketing Organization

  3. Oct 31, 2014

    Prinston Inc — Marketing Organization

  4. Nov 27, 2015

    Jubilant Innovation Ltd. — Marketing Organization

  5. Jun 10, 2016

    Lannett Company, Inc. — Marketing Organization

  6. Jan 20, 2017

    Lupin — Marketing Organization

  7. Jun 20, 2017

    Actavis — Marketing Organization

  8. Jun 20, 2017

    Allergan PLC (2015) — Marketing Organization

  9. Jun 12, 2018

    Sciecure Pharma Inc — Marketing Organization

2020s

  1. Feb 16, 2021

    Shijiazhuang Pharma Group (CSPC) — Marketing Organization

  2. Aug 11, 2021

    Epic Pharma Llc — Marketing Organization

  3. Aug 11, 2021

    Sinotherapeutics — Marketing Organization

  4. Aug 27, 2021

    Cadila Healthcare — Marketing Organization

  5. Sep 3, 2021

    Novitium Pharma — Marketing Organization

  6. Sep 3, 2021

    Ani Pharmaceuticals — Marketing Organization

  7. Nov 2, 2021

    Yiling Pharmaceutical Inc. — Marketing Organization

  8. Sep 24, 2025

    Alembic — Marketing Organization

  9. Mar 5, 2026

    Annora Pharma — Marketing Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedDec 29, 1992

Chemistry & pharmacology

Loading structure…

SMILES

FC1=CC=C(C=C1)[C@@H]2CCNC[C@H]2COC3=CC4=C(OCO4)C=C3
Mol. weight
329.3654 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
  • (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
  • (3s-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
  • (3s-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
  • brisdelle
  • brl-29060
  • brl-29060
  • brl 29060a
  • brl 29060a
  • brl 29060a
  • brl 29060a
  • brl 29060a
  • brl 29060a
  • brl-29060a
  • paroxetina
  • paroxetina
  • paroxetine
  • paroxetine
  • paroxetine
  • paroxetine
  • paroxetine
  • paroxetine
  • paroxetine
  • paroxetine
  • paroxetine hcl
  • paroxetine hcl
  • paroxetine hcl
  • paroxetine hydrochloride
  • paroxetine hydrochloride
  • paroxetine hydrochloride
  • paroxetine hydrochloride
  • paroxetine hydrochloride anhydrous
  • paroxetine hydrochloride hemihydrate
  • paroxetine hydrochloride hemihydrate
  • paroxetine hydrochloride hydrate
  • paroxetine mesilate
  • paroxetine mesylate
  • paroxetine mesylate
  • paroxetine mesylate
  • paroxetine mesylate
  • paroxetine mesylate
  • paroxetinum
  • paroxetinum
  • paxetil
  • paxil
  • paxil
  • paxil
  • paxil
  • paxil
  • paxil [as hydrochloride]
  • paxil cr
  • paxil cr
  • pexeva
  • pexeva
  • pot.mes
  • pot.mes
  • seroxat
  • seroxat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07070232Phase 1/Phase 2 (Phase 2)Aug 12, 2025Biontech
NCT07057011N/AJul 1, 2025South Valley University
NCT06957210N/AMay 6, 2025CMH Nowshera, Pakistan Army
NCT06957223N/AMay 6, 2025CMH Nowshera, Pakistan Army
NCT06796946Early Phase 1 (Phase 1)Apr 30, 2025University of Huelva
NCT07025590N/AApr 22, 2025Shantou University
NCT06799169Phase 4Mar 31, 2025University of California, Irvine
NCT06763484Phase 2Jan 1, 2025Universidad Nacional Autonoma de Honduras
NCT06232109Phase 1Feb 22, 2024Asceneuron S.A., QPS
NCT06203275Phase 3Jan 31, 2024Tanta University
NCT06231745Phase 3Jan 31, 2024Tanta University
NCT06065735Phase 1Sep 29, 2023GlaxoSmithKline
NCT05992428Phase 1Aug 22, 2023Dong-A Pharmaceutical
NCT05725837Phase 2Jun 10, 2023Universidade do Extremo Sul Catarinens
NCT06358014N/AMay 12, 2023Capital Medical University
NCT06025474Phase 3Jan 1, 2023University of Naples Frederico II
NCT05637671Phase 3Dec 31, 2022Cairo University
NCT05175430Phase 1Oct 24, 2022University of Basel
NCT05470465Phase 1Sep 1, 2022Food and Drug Administration, Leiden University, Spaulding Clinical Research Inc.
NCT05353543N/AMay 1, 2022Hangzhou First People Hospital, Zhejiang University
Showing 20 of 240 trials
Page 1 / 12

Organizations

Research & Development (222)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit463251998
National Institute of Mental Health (NIMH)Government18341998
Department of Veteran AffairsGovernment151141996
PfizerFor profit10942003
Harvard UniversityAcademic/Hospital9741998
Columbia UniversityAcademic/Hospital8641999
Capital Medical UniversityAcademic/Hospital6532011
Duke UniversityAcademic/Hospital6522002
Emory UniversityAcademic/Hospital6332003
Sungkyunkwan UniversityAcademic/Hospital6621999
University of PittsburghAcademic/Hospital6431998
OtsukaFor profit5522009
AstraZenecaFor profit4322005
MylanFor profit4412005
Noven TherapeuticsFor profit4432008
PRACSFor profit4012005
SanofiFor profit4422003
Zhejiang UniversityAcademic/Hospital4412022
Eli LillyFor profit3332004
Forest LaboratoriesFor profit3232011
222 organizations
Page 1 / 12

Marketing (37)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGJun 20, 2017
AlembicFor profitMKTGSep 24, 2025
Allergan PLC (2015)For profitMKTGJun 20, 2017
Ani PharmaceuticalsFor profitMKTGSep 3, 2021
Annora PharmaFor profitMKTGMar 5, 2026
ApotexFor profitNDA2Dec 29, 1992
ApotexFor profitMKTGJul 30, 2003
ApotexFor profitSYNDec 4, 2006
ApotexFor profitNDADec 29, 1992
Aurobindo PharmaFor profitMKTGJul 25, 2007
Aurobindo PharmaFor profitSYNJun 29, 2007
Boehringer IngelheimFor profitMKTGJun 29, 2007
Cadila HealthcareFor profitMKTGAug 27, 2021
Chartwell PharmaceuticalsFor profitMKTGAug 15, 2005
Epic Pharma LlcFor profitMKTGAug 11, 2021
Jubilant Innovation Ltd.For profitMKTGNov 27, 2015
LEGACY PHARMAFor profitMKTGJun 28, 2013
Lannett Company, Inc.For profitMKTGJun 10, 2016
LupinFor profitMKTGJan 20, 2017
LupinFor profitSYNJan 20, 2017
MylanFor profitSYNJun 29, 2007
MylanFor profitMKTGMar 8, 2004
Novitium PharmaFor profitMKTGSep 3, 2021
Oxford PharmaceuticalsFor profitMKTGJun 21, 2010
PHARMOBEDIENTFor profitMKTGMar 8, 2004
Prinston IncFor profitMKTGOct 31, 2014
Roxane LaboratoriesFor profitMKTGJun 29, 2007
Sciecure Pharma IncFor profitMKTGJun 12, 2018
Sebela PharmaceuticalsFor profitNDA2Jul 3, 2003
Shijiazhuang Pharma Group (CSPC)For profitMKTGFeb 16, 2021
SinotherapeuticsFor profitMKTGAug 11, 2021
Sun PharmaceuticalsFor profitMKTGJun 29, 2007
TevaFor profitSYNAug 15, 2005
TevaFor profitMKTGJun 29, 2007
Upsher-Smith LaboratoriesFor profitMKTGMar 8, 2004
Yiling Pharmaceutical Inc.For profitMKTGNov 2, 2021
Zydus Discovery DMCCFor profitMKTGMar 7, 2007